|
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評論] [本類其他產品] [本類其他供應商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷售商： 北京啟維益成科技有限公司 | 查看該公司所有產品 >> |
| |||||||||||||||||||||||||||||||||||||||
| application information | ||
| recommended dilution | needs to be determined for each application | |
| expected | apparent MW | n.a. | |
| confirmed reactivity | human, mouse, rat, dog | |
| predicted reactivity | higher plants | |
| not reactive in | no confirmed exceptions from predicted reactivity known in the moment | |
| additional information | antibody recognizes 3-nitrotyrosine moieties. No detectable crossreactivity 0.7μg/ml was sufficient for detection of 5 μg SIN-1 treated BSA by Western Blot using standard ECL | |
| selected references | Antibody used in western blot and ELISA: Girault et al. (2001).Immunodetection of 3-nitrotyrosine in the liver of zymosan-treated rats with a new monoclonal antibody: comparison to analysis by HPLC. Free Radical Biology and Medicine, 31 (11): 1375-1387. Gow et al. (2004).Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol. 287(2): L262-8. Antibody used in immunohistochemistry: Pfister et al. (2002). Inducible nitric oxide synthase and nitrotyrosine in listeric encephalitis: a cross-species study in ruminants. Vet Pathol. 39: 190-199. | |
